Skip to main content
. 2019 Nov 28;9(1):9–19. doi: 10.1530/EC-19-0340

Figure 1.

Figure 1

AR transcript expression is increased with acquired AR-antagonists resistance. (A) MTT cytotoxicity assays of LNCaP, LNCaPBicR and LNCaPEnzR cells treated with increasing concentrations of either bicalutamide (left hand side) and enzalutamide (right hand side), at 0–100 µM for 96 h. (B) MTT cytotoxicity assays of VCaP, VCaPBicR and VCaPEnzR cells treated with increasing concentrations of either bicalutamide (left hand side) and enzalutamide (right hand side), at 0–100 µM for 96 h. (C) qPCR analysis of AR and PSA expression levels in four prostate cancer cell lines, as indicated. (D) qPCR analysis of AR expression levels in parental and resistant prostate cancer cell lines as indicated. Data represent the mean and s.e. from three independent replicates. Data are normalised to housekeeping genes GAPDH, RPL19 and β-actin. (E) Western blot for AR levels from LNCaP and LNCaP/Bic/Enz cells, normalised to β-actin. Statistical analysis * (P = 0.05), ** (P = 0.01) from a t-test.